Premium
Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis
Author(s) -
Darlington Peter J.,
Boivin MarieNoëlle,
Renoux Christel,
François Moïra,
Galipeau Jacques,
Freedman Mark S.,
Atkins Harold L.,
Cohen Jeffrey A.,
Solchaga Luis,
BarOr Amit
Publication year - 2010
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.22065
Subject(s) - mesenchymal stem cell , multiple sclerosis , proinflammatory cytokine , immune system , immunology , interleukin 17 , cytokine , bone marrow , medicine , biology , cancer research , inflammation , microbiology and biotechnology
Human mesenchymal stem cells (hMSCs) are being considered for clinical trials of multiple sclerosis (MS). We examined the effects of adult bone marrow‐derived hMSCs on responses of primary human Th1, Th17, and Th1/17 double‐expressing T‐cell subsets, all implicated in MS. As expected, soluble products from hMSCs inhibited Th1 responses; however, Th17 responses were increased. Secretion of interleukin (IL)‐10, considered anti‐inflammatory, was decreased. Pretreating hMSCs with the proinflammatory cytokine IL‐1β accentuated these effects, and caused decreases in the Th1/17 subset. These findings underscore the importance of further preclinical work and immune‐monitoring to define hMSC effects on disease‐relevant immune responses under variable conditions. ANN NEUROL 2010